search
Back to results

LOD vs Gn in Anovulatory PCOs Resistant to First Line Agents

Primary Purpose

Polycystic Ovary Syndrome, Anovulation

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Laparoscopic ovarian drilling
Recombinant FSH (rFSH)
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Polycystic Ovary Syndrome focused on measuring Laparoscopic ovarian drilling, Gonadotrophins, Polycystic ovary syndrome, Anovulation, PCOs, Clomiphene resistant, Letrozole resistant

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

anovulatory polycystic ovary syndrome resistant to first line ovulation induction.

  • Polycystic ovary Syndrome defined by Rotterdam's criteria 2003
  • Clomiphene resistance defined as failure to ovulate with a dose of 150mg per day for 5 days for 3 cycles
  • Letrozole resistance defined as failure to ovulate with a dose of 7.5 mg per day for 5 days for 3 cycles

Exclusion Criteria:

  • women's age < 18 years or ≥ 40 years.
  • BMI > 40 kg/m2
  • Patient with hyperprolactinaemia (serum prolactin above normal limits)
  • Patients with hypogonadotropic hypogonadism (low serum FSH and LH)
  • Patients with anovulation due to ovarian failure (serum FSH higher than normal limits)
  • Male infertility
  • Tubal abnormality, Known endometriosis, adenomyosis, uterine myomas or any other detected cause of female infertility
  • History of ovarian surgery as laparoscopic ovarian drilling, ovarian cystectomy or oophorectomy
  • History of pelvic radiation
  • Patient recently treated with any type of induction of ovulation in the last three months.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Surgical treatment strategy:

    Gonadotrophins treatment strategy

    Arm Description

    Outcomes

    Primary Outcome Measures

    Live Birth
    defined as the number of births resulted in live babies after the age of viability (24th week of pregnancy)

    Secondary Outcome Measures

    Full Information

    First Posted
    March 26, 2020
    Last Updated
    October 12, 2020
    Sponsor
    Assiut University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04325295
    Brief Title
    LOD vs Gn in Anovulatory PCOs Resistant to First Line Agents
    Official Title
    Laparoscopic Ovarian Drilling Versus Gonadotrophins for Anovulatory Polycystic Ovary Syndrome Resistant to First Line Ovulation Induction: a Randomized Controlled Trial.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    December 2020 (Anticipated)
    Primary Completion Date
    June 2022 (Anticipated)
    Study Completion Date
    August 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Assiut University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    PCOS is a complex disease that is diagnosed by the presence of two of the following three: oligo/anovulation, clinical and/or biochemical hyperandrogenism, or polycystic ovaries by ultrasound . PCOS affects 4% to 21% of females in reproductive age . Although subfertility is abundant in women with PCOS, a majority of these women will achieve pregnancy naturally or by treatment. Different treatment modalities are present for ovulation induction. Life style modifications including weight loss are encouraged for those who are overweight or obese. Pharmacological induction of ovulation represent the first line therapy for induction of ovulation. Options include aromatase inhibitors (Letrozole), Clomiphene Citrate (CC) or Metformin, alone or in combinations. For second line treatment either Gonadotropins (Gn) or laparoscopic ovarian surgery (LOS) are the recommended options . the objective of the trial is to study the effectiveness and safetey of surgical induction of ovulation strategy and compare it to medical induction strategy with Gonadotropins
    Detailed Description
    PCOS is a complex disease that is diagnosed by the presence of two of the following three: oligo/anovulation, clinical and/or biochemical hyperandrogenism, or polycystic ovaries by ultrasound . PCOS affects 4% to 21% of females in reproductive age . Although subfertility is abundant in women with PCOS, a majority of these women will achieve pregnancy naturally or by treatment. Different treatment modalities are present for ovulation induction. Life style modifications including weight loss are encouraged for those who are overweight or obese. Pharmacological induction of ovulation represent the first line therapy for induction of ovulation. Options include aromatase inhibitors (Letrozole), Clomiphene Citrate (CC) or Metformin, alone or in combinations. For second line treatment either Gonadotropins (Gn) or laparoscopic ovarian surgery (LOS) are the recommended options . Systematic reviews done comparing LOD to Gn found no differences in live birth, clinical pregnancy or miscarriage rates. However, there was significant decrease in OHSS and multiple pregnancies with LOD . Giving these advantages together with being cheap, the surgical strategy may be a more favorable choice as second line treatment of anovulation . Also several randomised controlled trial (RCTs) reported normalization of ovarian reserve parameters after LOD, making it a long-lasting option compared to the one-cycle effect of medical treatment the objective of the trial is to study the effectiveness and safetey of surgical induction of ovulation strategy and compare it to medical induction strategy with Gonadotropins

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Polycystic Ovary Syndrome, Anovulation
    Keywords
    Laparoscopic ovarian drilling, Gonadotrophins, Polycystic ovary syndrome, Anovulation, PCOs, Clomiphene resistant, Letrozole resistant

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    200 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Surgical treatment strategy:
    Arm Type
    Active Comparator
    Arm Title
    Gonadotrophins treatment strategy
    Arm Type
    Active Comparator
    Intervention Type
    Procedure
    Intervention Name(s)
    Laparoscopic ovarian drilling
    Intervention Description
    LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached > 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy
    Intervention Type
    Drug
    Intervention Name(s)
    Recombinant FSH (rFSH)
    Intervention Description
    A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
    Primary Outcome Measure Information:
    Title
    Live Birth
    Description
    defined as the number of births resulted in live babies after the age of viability (24th week of pregnancy)
    Time Frame
    within 12 months after of end treatment strategy

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    40 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: anovulatory polycystic ovary syndrome resistant to first line ovulation induction. Polycystic ovary Syndrome defined by Rotterdam's criteria 2003 Clomiphene resistance defined as failure to ovulate with a dose of 150mg per day for 5 days for 3 cycles Letrozole resistance defined as failure to ovulate with a dose of 7.5 mg per day for 5 days for 3 cycles Exclusion Criteria: women's age < 18 years or ≥ 40 years. BMI > 40 kg/m2 Patient with hyperprolactinaemia (serum prolactin above normal limits) Patients with hypogonadotropic hypogonadism (low serum FSH and LH) Patients with anovulation due to ovarian failure (serum FSH higher than normal limits) Male infertility Tubal abnormality, Known endometriosis, adenomyosis, uterine myomas or any other detected cause of female infertility History of ovarian surgery as laparoscopic ovarian drilling, ovarian cystectomy or oophorectomy History of pelvic radiation Patient recently treated with any type of induction of ovulation in the last three months.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Khaled M Attyia
    Phone
    +201005503250
    Email
    khaled.hussien@med.aun.edu.eg
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Sayed A Abdallah
    Organizational Affiliation
    Professor of obstetric and Gynecology,Faculty of Medicine,Assuit University O
    Official's Role
    Study Director
    First Name & Middle Initial & Last Name & Degree
    Essam R Othman
    Organizational Affiliation
    Assistant Professor of Obstetrics and Gynecology,Faculty of Medicine, Assuit University
    Official's Role
    Study Director
    First Name & Middle Initial & Last Name & Degree
    Mustafa B Mohammed
    Organizational Affiliation
    Assistant professor of Obstetrics and Gynecology, Faculty of Medicine,Assuit University
    Official's Role
    Study Director
    First Name & Middle Initial & Last Name & Degree
    Ahmed M Alaa Eldin
    Organizational Affiliation
    Lecturer of Obstetrics and Gynecology,Faculty of Medicine,Assuit University
    Official's Role
    Study Director
    First Name & Middle Initial & Last Name & Degree
    Karim S Abdallah
    Organizational Affiliation
    Assistant lecturer of Obstetrics and Gynecology,Faculty of Medicine,Assuit University
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    30679436
    Citation
    Farquhar CM, Bhattacharya S, Repping S, Mastenbroek S, Kamath MS, Marjoribanks J, Boivin J. Female subfertility. Nat Rev Dis Primers. 2019 Jan 24;5(1):7. doi: 10.1038/s41572-018-0058-8.
    Results Reference
    background
    PubMed Identifier
    30648738
    Citation
    Weiss NS, Kostova E, Nahuis M, Mol BWJ, van der Veen F, van Wely M. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019 Jan 16;1(1):CD010290. doi: 10.1002/14651858.CD010290.pub3.
    Results Reference
    background
    PubMed Identifier
    27233760
    Citation
    Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016 Jul;106(1):6-15. doi: 10.1016/j.fertnstert.2016.05.003. Epub 2016 May 24.
    Results Reference
    background
    PubMed Identifier
    15242999
    Citation
    van Wely M, Bayram N, Bossuyt PM, van der Veen F. Laparoscopic electrocautery of the ovaries versus recombinant FSH in clomiphene citrate-resistant polycystic ovary syndrome. Impact on women's health-related quality of life. Hum Reprod. 2004 Oct;19(10):2244-50. doi: 10.1093/humrep/deh406. Epub 2004 Jul 8.
    Results Reference
    background
    PubMed Identifier
    19347705
    Citation
    Api M. Is ovarian reserve diminished after laparoscopic ovarian drilling? Gynecol Endocrinol. 2009 Mar;25(3):159-65. doi: 10.1080/09513590802585605.
    Results Reference
    background
    PubMed Identifier
    31497757
    Citation
    Debras E, Fernandez H, Neveu ME, Deffieux X, Capmas P. Ovarian drilling in polycystic ovary syndrome: Long term pregnancy rate. Eur J Obstet Gynecol Reprod Biol X. 2019 Aug 13;4:100093. doi: 10.1016/j.eurox.2019.100093. eCollection 2019 Oct.
    Results Reference
    background
    PubMed Identifier
    12407038
    Citation
    Amer SA, Banu Z, Li TC, Cooke ID. Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and ultrasonographic outcomes. Hum Reprod. 2002 Nov;17(11):2851-7. doi: 10.1093/humrep/17.11.2851.
    Results Reference
    background
    PubMed Identifier
    22696324
    Citation
    Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD001122. doi: 10.1002/14651858.CD001122.pub4.
    Results Reference
    background
    PubMed Identifier
    23001778
    Citation
    Nahuis MJ, Oude Lohuis E, Kose N, Bayram N, Hompes P, Oosterhuis GJ, Kaaijk EM, Cohlen BJ, Bossuyt PP, van der Veen F, Mol BW, van Wely M. Long-term follow-up of laparoscopic electrocautery of the ovaries versus ovulation induction with recombinant FSH in clomiphene citrate-resistant women with polycystic ovary syndrome: an economic evaluation. Hum Reprod. 2012 Dec;27(12):3577-82. doi: 10.1093/humrep/des336. Epub 2012 Sep 20.
    Results Reference
    background

    Learn more about this trial

    LOD vs Gn in Anovulatory PCOs Resistant to First Line Agents

    We'll reach out to this number within 24 hrs